Overview

A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza

Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the safety of inhaled SNG001 and the ability of inhaled SNG001 to 'switch on' the cells' anti-viral defences in patients with chronic obstructive pulmonary disease (COPD). The study consist of two parts. Part 1 will assess the safety of inhaled SNG001 in ten patients with stable COPD. Part 2 will assess efficacy and safety of inhaled SNG001 in 120 patients with COPD with a cold or COPD exacerbation.
Phase:
Phase 2
Details
Lead Sponsor:
Synairgen Research Ltd.
Treatments:
Interferon beta-1a
Interferon-beta
Interferons